Exploratory toxicology as an integrated part of drug discovery. Part II: Screening strategies.

In an effort to reduce toxicity-related attrition, different strategies have been implemented throughout the pharmaceutical industry. Previously (in Part I), we have outlined our 'integrated toxicology' strategy, which aims to provide timely go/no-go decisions (fail early) but also to show a direction to the drug discovery teams (showing what will not fail). In this review (Part II of the series) we describe our compound testing strategies with respect to cardiovascular safety, hepatotoxicity, genotoxicity, immunotoxicity and exploratory in vivo toxicity. We discuss the in vitro, ex vivo and in vivo assays and models we employ to assess safety risks and optimize compound series during the drug discovery process, including their predictivity and the decisions they generate.

[1]  S. Walker,et al.  The value of chronic animal toxicology studies of pharmaceutical compounds: A retrospective analysis. , 1985, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[2]  Stephen D Dertinger,et al.  In vitro micronucleus assay scored by flow cytometry provides a comprehensive evaluation of cytogenetic damage and cytotoxicity. , 2007, Mutation research.

[3]  Peter V. Henstock,et al.  Cellular imaging predictions of clinical drug-induced liver injury. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[4]  T. Singer,et al.  Comparative evaluation of in silico systems for ames test mutagenicity prediction: scope and limitations. , 2011, Chemical research in toxicology.

[5]  Jean-Pierre Valentin,et al.  Approaches to seizure risk assessment in preclinical drug discovery. , 2009, Drug discovery today.

[6]  P Smith,et al.  Concordance of the toxicity of pharmaceuticals in humans and in animals. , 2000, Regulatory toxicology and pharmacology : RTP.

[7]  Warren W Ku,et al.  An evaluation of the sensitivity of the Ames assay to discern low-level mutagenic impurities. , 2007, Regulatory toxicology and pharmacology : RTP.

[8]  W. Freebern,et al.  Methods: Implementation of in vitro and ex vivo phagocytosis and respiratory burst function assessments in safety testing , 2013, Journal of immunotoxicology.

[9]  A. Stepan,et al.  Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. , 2011, Chemical research in toxicology.

[10]  Richard Morrison,et al.  Exploratory drug safety: a discovery strategy to reduce attrition in development. , 2009, Journal of pharmacological and toxicological methods.

[11]  Frank D Sistare,et al.  A performance evaluation of three drug-induced liver injury biomarkers in the rat: alpha-glutathione S-transferase, arginase 1, and 4-hydroxyphenyl-pyruvate dioxygenase. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[12]  Cynthia A Afshari,et al.  Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[13]  Katie Smith,et al.  Reduction of misleading ("false") positive results in mammalian cell genotoxicity assays. II. Importance of accurate toxicity measurement. , 2012, Mutation research.

[14]  M. Mocanu,et al.  Retrograde heart perfusion: the Langendorff technique of isolated heart perfusion. , 2011, Journal of molecular and cellular cardiology.

[15]  Katie Smith,et al.  Reduction of misleading ("false") positive results in mammalian cell genotoxicity assays. I. Choice of cell type. , 2012, Mutation research.

[16]  P. Bernardi,et al.  High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening , 2006, Archives of Toxicology.

[17]  N. Prats,et al.  Multiparametric immunotoxicity screening in mice during early drug development. , 2012, Toxicology letters.

[18]  Ard Teisman,et al.  Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening? , 2009, Journal of pharmacological and toxicological methods.

[19]  R. Snyder,et al.  Comparison of the results of a modified miniscreen and the standard bacterial reverse mutation assays , 2000, Environmental and molecular mutagenesis.

[20]  Gareth J Waldron,et al.  Reducing safety-related drug attrition: the use of in vitro pharmacological profiling , 2012, Nature Reviews Drug Discovery.

[21]  J. Descotes.  Safety immunopharmacology: Evaluation of the adverse potential of pharmaceuticals on the immune system , 2012, Journal of Pharmacological and Toxicological Methods.

[22]  Min Goo Lee,et al.  MRP2 haplotypes confer differential susceptibility to toxic liver injury , 2007, Pharmacogenetics and genomics.

[23]  E Zeiger,et al.  Identification of rodent carcinogens and noncarcinogens using genetic toxicity tests: premises, promises, and performance. , 1998, Regulatory toxicology and pharmacology : RTP.

[24]  Jorrit J Hornberg,et al.  A high content screening assay to predict human drug-induced liver injury during drug discovery. , 2013, Journal of pharmacological and toxicological methods.

[25]  J. Pennings,et al.  Application of toxicogenomics in hepatic systems toxicology for risk assessment: acetaminophen as a case study. , 2011, Toxicology and applied pharmacology.

[26]  Raffaella Corvi,et al.  How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: Report of an ECVAM Workshop. , 2007, Mutation research.

[27]  D. Sanderson,et al.  Computer Prediction of Possible Toxic Action from Chemical Structure; The DEREK System , 1991, Human & experimental toxicology.

[28]  Esther F. Schmid,et al.  Drug withdrawals and the lessons within. , 2006, Current opinion in drug discovery & development.

[29]  Sheryl E. Koch,et al.  The L-type calcium channel in the heart: the beat goes on. , 2005, The Journal of clinical investigation.

[30]  G. Cantelli-forti,et al.  On the metabolizing systems for short-term genotoxicity assays: a review. , 1997, Mutation research.

[31]  Yan Li,et al.  In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. , 2012, Chemical research in toxicology.

[32]  A. Sanbuissho,et al.  Evaluation of primary and secondary responses to a T-cell-dependent antigen, keyhole limpet hemocyanin, in rats , 2013, Journal of immunotoxicology.

[33]  Minoru Nishida,et al.  Potentials and limitations of nonclinical safety assessment for predicting clinical adverse drug reactions: correlation analysis of 142 approved drugs in Japan. , 2013, The Journal of toxicological sciences.

[34]  F. Dedeoğlu.  Drug-induced autoimmunity , 2009, Current opinion in rheumatology.

[35]  R. Woutersen,et al.  Toward in vitro biomarkers for developmental toxicity and their extrapolation to the in vivo situation , 2012, Expert opinion on drug metabolism & toxicology.

[36]  J. Descotes,et al.  NK-cell activity in immunotoxicity drug evaluation. , 2003, Toxicology.

[37]  Jean-Pierre Valentin,et al.  Impact and prevalence of safety pharmacology-related toxicities throughout the pharmaceutical life cycle , 2010 .

[38]  Raffaella Corvi,et al.  Analysis of published data for top concentration considerations in mammalian cell genotoxicity testing. , 2010, Mutagenesis.

[39]  J. Dean,et al.  Immunotoxicology assessment in the pharmaceutical industry. , 1998, Toxicology Letters.

[40]  Peter Greaves,et al.  First dose of potential new medicines to humans: how animals help , 2004, Nature Reviews Drug Discovery.

[41]  N. Chalasani,et al.  Risk factors for idiosyncratic drug-induced liver injury. , 2010, Gastroenterology.

[42]  Neil Kaplowitz,et al.  Idiosyncratic drug hepatotoxicity , 2005, Nature Reviews Drug Discovery.

[43]  R. Walmsley,et al.  Nongenotoxic apoptosis inducers do not produce misleading positive results in the TK6 cell-based GADD45a-GFP genotoxicity assay. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[44]  E. Moors,et al.  The ability of animal studies to detect serious post marketing adverse events is limited. , 2012, Regulatory toxicology and pharmacology : RTP.

[45]  Dragos Horvath,et al.  Predicting ADME properties and side effects: the BioPrint approach. , 2003, Current opinion in drug discovery & development.

[46]  S. Roychowdhury,et al.  Mechanisms of drug-induced delayed-type hypersensitivity reactions in the skin , 2005, The AAPS Journal.

[47]  Gary Gintant,et al.  An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation. , 2011, Pharmacology & therapeutics.

[48]  Pal Pacher,et al.  Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? , 2004, Current pharmaceutical design.

[49]  A. Tall,et al.  The failure of torcetrapib: was it the molecule or the mechanism? , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[50]  J. Valentin,et al.  On the relationship between block of the cardiac Na+ channel and drug‐induced prolongation of the QRS complex , 2011, British journal of pharmacology.

[51]  Michael Markert,et al.  Developing a strategy for the nonclinical assessment of proarrhythmic risk of pharmaceuticals due to prolonged ventricular repolarization. , 2004, Journal of pharmacological and toxicological methods.

[52]  David Kirkland,et al.  A core in vitro genotoxicity battery comprising the Ames test plus the in vitro micronucleus test is sufficient to detect rodent carcinogens and in vivo genotoxins. , 2011, Mutation research.

[53]  M. Kamber,et al.  Direct comparison of the Ames microplate format (MPF) test in liquid medium with the standard Ames pre-incubation assay on agar plates by use of equivocal to weakly positive test compounds. , 2012, Mutation research.

[54]  A. Camm,et al.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.

[55]  Richard M Walmsley,et al.  High-specificity and high-sensitivity genotoxicity assessment in a human cell line: validation of the GreenScreen HC GADD45a-GFP genotoxicity assay. , 2006, Mutation research.

[56]  F. Cools,et al.  The fentanyl/etomidate-anaesthetised beagle (FEAB) dog: a versatile in vivo model in cardiovascular safety research. , 2009, Journal of pharmacological and toxicological methods.

[57]  J. Valentin,et al.  An introduction to QT interval prolongation and non‐clinical approaches to assessing and reducing risk , 2010, British journal of pharmacology.

[58]  Jorrit J Hornberg,et al.  Exploratory toxicology as an integrated part of drug discovery. Part I: Why and how. , 2014, Drug discovery today.

[59]  Paul Cahill,et al.  GADD45a-GFP GreenScreen HC assay results for the ECVAM recommended lists of genotoxic and non-genotoxic chemicals for assessment of new genotoxicity tests. , 2010, Mutation research.

[60]  Borje Darpo,et al.  ICH E14: A New Regulatory Guidance on the Clinical Evaluation of QT/QTc Internal Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs , 2005 .

[61]  Ivan Rusyn,et al.  Predicting drug-induced hepatotoxicity using QSAR and toxicogenomics approaches. , 2011, Chemical research in toxicology.

[62]  J. Tamargo,et al.  Investigational positive inotropic agents for acute heart failure. , 2009, Cardiovascular & hematological disorders drug targets.